Radiofrequency-ablation of unresectable primary and secondary liver tumors: Results in 88 patients

Philipp Hildebrand*, Markus Kleemann, Uwe J. Roblick, Lutz Mirow, Matthias Birth, Thorsten Leibecke, Hans Peter Bruch

*Korrespondierende/r Autor/-in für diese Arbeit
33 Zitate (Scopus)


Background and aims: Radiofrequency-ablation (RFA) is increasingly used for destruction of unresectable primary and secondary liver tumors. We report our experience in the use of RFA for the management of unresectable hepatic malignancies. Patients and methods: Between February 2000 and December 2004 we have undertaken 120 RFA procedures to ablate 426 unresectable primary or metastatic liver tumors in 88 patients. RFA was performed via laparotomy (n=68), laparoscopy (n=9) or a percutaneous approach (n=43). Primary liver cancer was treated in seven patients (8%) and metastatic liver tumors were treated in 81 patients (92%). All patients were followed to assess complications, treatment response and recurrence of malignant disease. Results: Procedure-related complication rate was low (3.4%). During a mean follow-up of 21.2 months, 15 patients had local tumor progression (17%), 21 patients (23,9%) had new malignant disease and 27 patients (30.7%) died from intervention-unrelated complications of their malignant disease. Additional liver lesions were identified in 27 (35%) of 77 cases by intraoperative ultrasound. Thirty-six patients received simultaneous resection and RFA. Conclusion: RFA is a safe, well-tolerated and effective treatment for patients with unresectable primary and secondary liver malignancies.

ZeitschriftLangenbeck's Archives of Surgery
Seiten (von - bis)118-123
PublikationsstatusVeröffentlicht - 04.2006

Strategische Forschungsbereiche und Zentren

  • Profilbereich: Lübeck Integrated Oncology Network (LION)


Untersuchen Sie die Forschungsthemen von „Radiofrequency-ablation of unresectable primary and secondary liver tumors: Results in 88 patients“. Zusammen bilden sie einen einzigartigen Fingerprint.